Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC220 and Doxorubicin in Advanced Solid Tumours
NCT06815575Phase 1Recruiting
- Sponsor
- Racura Oncology
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of RC220 in solid tumor (2 arms), sponsored by Racura Oncology. Primary endpoints: Dose Limiting Toxicities at 21 days and Treatment Emergent Adverse Events and Serious Adverse Events at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
RC220
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06815575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815575.